Latest Period
Q1 2026
Security Snapshot
Lakefront Biotherapeutics NV - Ordinary shares, no par value (LKFT) Institutional Ownership
CUSIP: 36315X101
13F Institutional Holders and Ownership History from Q2 2015 to Q1 2026
Institutions Reporting
90
Shares (Excl. Options)
31,262,417
Price
$30.00
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary shares, no par value
- Symbol
- LKFT on Nasdaq
- All holders as of 31 Mar 2026
- Q1 2026
- Total 13F shares
- 31,262,417
- Total 13F value
- $937,850,803
- Portfolio coverage rank
- 0%
- Share change
- -43,526
- Value change
- -$1,945,695
- Number of holders
- 90
- Shares outstanding
- 66,186,595
- SEC-reported price per share
- $27.33
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- LKFT - Lakefront Biotherapeutics NV - Ordinary shares, no par value is tracked under CUSIP 36315X101.
- 90 institutions reported positions in Q1 2026.
- 3 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 92 to 90 between Q4 2025 and Q1 2026.
- SEC-reported value moved from $1,030,612,133 to $937,850,803.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 90 institutions filings for Q1 2026.
Security key
36315X101
Latest holder period
Q1 2026
13F holders
90
13D/G owners
3
CIK / CUSIP context first
Open Q1 2026 holders
LKFT full holder history
Lakefront Biotherapeutics NV SEC filings
Lakefront Biotherapeutics NV company facts
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36315X101:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
3
Security
LKFT
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 30% | $555,786,955 | 20,981,010 | Gilead Sciences, Inc. | 07 Jan 2025 | |||
| EcoR1 Capital, LLC | 13% | +12% | $243,919,471 | +$25,507,847 | 8,714,522 | +12% | EcoR1 Capital, LLC | 24 Jul 2025 |
| TANG CAPITAL MANAGEMENT LLC | 8.4% | +11% | $192,587,107 | +$22,486,521 | 5,559,674 | +13% | TANG CAPITAL MANAGEMENT, LLC | 27 Oct 2025 |
As of 31 Mar 2026, 90 institutional investors reported holding 31,262,417 shares of Lakefront Biotherapeutics NV - Ordinary shares, no par value (LKFT). This represents 47% of the company’s total 66,186,595 outstanding shares.
13F concentration
Top 25 institutional shareholders
Largest 13F positions for this security by reported shares and value.
Top holder share
46%
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| GILEAD SCIENCES, INC. | 25% | 16,707,477 | 0% | 24% | $501,224,310 |
| TANG CAPITAL MANAGEMENT LLC | 5.7% | 3,785,991 | -3.4% | 5.8% | $113,579,730 |
| Madison Avenue Partners, LP | 3.7% | 2,465,179 | +11% | 3.2% | $73,955,370 |
| EcoR1 Capital, LLC | 2.5% | 1,667,119 | 0% | 2.1% | $50,013,570 |
| Prosight Management, LP | 2.3% | 1,550,000 | +44% | 7.6% | $46,500,000 |
| AMERIPRISE FINANCIAL INC | 2.2% | 1,424,674 | -1.8% | 0.01% | $42,740,220 |
| DME Capital Management, LP | 0.73% | 482,746 | 0% | 0.45% | $14,482,380 |
| SEGALL BRYANT & HAMILL, LLC | 0.64% | 426,412 | -4.8% | 0.18% | $12,792,360 |
| Point72 Asset Management, L.P. | 0.5% | 332,125 | -32% | 0.02% | $9,963,750 |
| RENAISSANCE TECHNOLOGIES LLC | 0.48% | 315,400 | +1.5% | 0.01% | $9,462,000 |
| BlackRock, Inc. | 0.47% | 312,106 | -0.69% | 0% | $9,363,180 |
| D. E. Shaw & Co., Inc. | 0.33% | 215,718 | -22% | 0.01% | $6,471,540 |
| UBS Group AG | 0.26% | 175,289 | -50% | 0% | $5,258,670 |
| DAFNA Capital Management LLC | 0.2% | 130,175 | 0% | 0.89% | $3,905,250 |
| CITADEL ADVISORS LLC | 0.19% | 124,428 | +39% | 0% | $3,732,840 |
| MILLENNIUM MANAGEMENT LLC | 0.16% | 107,912 | -68% | 0% | $3,237,360 |
| OLD MISSION CAPITAL LLC | 0.14% | 95,591 | 0.07% | $2,867,730 | |
| Man Group plc | 0.12% | 80,209 | +69% | 0% | $2,406,270 |
| Hudson Bay Capital Management LP | 0.12% | 77,500 | -54% | 0.01% | $2,325,000 |
| Tower Research Capital LLC (TRC) | 0.1% | 66,536 | +12042% | 0.05% | $1,996,080 |
| ALPS ADVISORS INC | 0.08% | 53,661 | -0.24% | 0.01% | $1,609,830 |
| ACADIAN ASSET MANAGEMENT LLC | 0.07% | 45,942 | +509% | 0% | $1,373,000 |
| GOLDMAN SACHS GROUP INC | 0.07% | 45,371 | +307% | 0% | $1,361,130 |
| HRT FINANCIAL LP | 0.07% | 45,168 | 0% | $1,355,000 | |
| AMERICAN CENTURY COMPANIES INC | 0.06% | 38,790 | +45% | 0% | $1,163,700 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
44
Latest
Q1 2026
Rows shown
1-25 of 44
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 31,262,417 | $937,850,803 | -$1,945,695 | $30.00 | 90 |
| 2025 Q4 | 31,396,165 | $1,030,612,133 | -$423,032 | $32.70 | 92 |
| 2025 Q3 | 31,401,256 | $1,087,732,117 | -$7,956,750 | $34.64 | 92 |
| 2025 Q2 | 31,697,765 | $887,221,465 | +$28,214,019 | $27.99 | 85 |
| 2025 Q1 | 31,070,295 | $780,194,528 | -$4,334,186 | $25.12 | 82 |
| 2024 Q4 | 31,079,138 | $856,919,857 | +$17,773,347 | $27.50 | 81 |
| 2024 Q3 | 13,663,353 | $393,374,763 | -$177,023,110 | $28.79 | 77 |
| 2024 Q2 | 19,935,693 | $494,012,131 | -$14,463,813 | $24.78 | 82 |
| 2024 Q1 | 20,486,366 | $659,634,802 | +$21,269,889 | $32.20 | 79 |
| 2023 Q4 | 19,790,623 | $804,487,651 | +$20,616,236 | $40.65 | 87 |
| 2023 Q3 | 19,171,399 | $662,382,310 | -$16,486,115 | $34.55 | 72 |
| 2023 Q2 | 19,708,613 | $801,351,937 | +$60,840,835 | $40.66 | 73 |
| 2023 Q1 | 18,215,508 | $703,834,822 | +$192,041,792 | $38.64 | 72 |
| 2022 Q4 | 13,177,559 | $584,821,554 | +$12,983,412 | $44.38 | 71 |
| 2022 Q3 | 12,911,798 | $550,549,123 | -$12,978,528 | $42.64 | 77 |
| 2022 Q2 | 12,900,644 | $719,839,590 | -$9,312,560 | $55.80 | 79 |
| 2022 Q1 | 12,830,797 | $795,810,983 | +$134,250,057 | $62.02 | 86 |
| 2021 Q4 | 10,793,402 | $595,046,185 | +$111,349,568 | $55.13 | 81 |
| 2021 Q3 | 8,551,124 | $449,836,824 | +$478,944 | $52.61 | 80 |
| 2021 Q2 | 7,506,771 | $517,197,342 | +$62,993,693 | $68.89 | 99 |
| 2021 Q1 | 6,565,519 | $505,977,352 | +$131,911,497 | $77.09 | 123 |
| 2020 Q4 | 4,564,667 | $452,130,046 | -$397,947,991 | $98.98 | 106 |
| 2020 Q3 | 7,422,842 | $1,053,286,217 | -$44,029,693 | $141.91 | 116 |
| 2020 Q2 | 7,628,171 | $1,504,806,578 | -$6,418,127 | $197.29 | 138 |
| 2020 Q1 | 7,635,004 | $1,496,203,411 | +$21,392,001 | $195.92 | 134 |